Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

101.69 +0.13 (+0.13%)
Streaming Delayed Price Updated: 3:15 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio? ↗
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
News headline image
Crude Oil Moves Lower; Moderna Shares Plunge ↗
 
Via Benzinga
News headline image
Exact Sciences Analysts Slash Their Forecasts After Q2 Results ↗
 
Via Benzinga
News headline image
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July ↗
 
Via Benzinga
Topics Stocks
News headline image
Peeling Back The Layers: Exploring Exact Sciences Through Analyst Insights ↗
 
Via Benzinga
News headline image
Expert Outlook: Exact Sciences Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Exact Sciences? ↗
 
Via Benzinga
News headline image
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat ↗
The company expects stronger second-half sales vs. the first half of 2024. 
Via Investor's Business Daily
News headline image
Exact Sciences (EXAS) Q2 2024 Earnings Call Transcript ↗
EXAS earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Exact Sciences Stock Climbs After Strong Q2 Results ↗
Exact Sciences shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the details from the report: 
Via Benzinga
News headline image
Exact Sciences Announces Second-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The strugglingh stock investor did a little bit of shopping on Tuesday, adding to some of her existing positions. 
Via The Motley Fool
News headline image
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption ↗
FDA approves Guardant Health's Shield blood test for colorectal cancer screening in adults 45+, marking the first FDA-approved blood test as a primary CRC screening option. Shield meets Medicare... 
Via Benzinga
News headline image
Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns ↗
The investment banking firm says these companies are among the best stocks to buy and have some strong tailwinds behind them. 
Via InvestorPlace
News headline image
This Cathie Wood Growth Stock Could Soar by 93%, According to Wall Street ↗
Investors shouldn't rush to buy the stock based on rosy short-term price targets. 
Via The Motley Fool
News headline image
Exact Sciences schedules second quarter 2024 earnings call
From Exact Sciences Corp.
Via Business Wire
News headline image
The 3 Best Personalized Medicine Stocks to Buy in July 2024 ↗
Explore promising personalized medicine stocks poised for growth as the industry expands, driven by advancements in genomic technologies. 
Via InvestorPlace
News headline image
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks 
Via News Direct
News headline image
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
Via MarketBeat
News headline image
Jefferies Says Buy These 3 Stocks for More Than Double-Digit Returns ↗
Jefferies Financial Group sees these three companies as prime candidates among stocks for double-digit returns. 
Via InvestorPlace
News headline image
Is It Time to Buy May's Worst-Performing Nasdaq Stocks? ↗
These two Nasdaq stocks are significantly cheaper today than they were just one month ago. 
Via The Motley Fool
News headline image
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness ↗
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
Via Benzinga
News headline image
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock ↗
 
Via Benzinga
News headline image
Top 4 Health Care Stocks That Are Preparing To Pump This Month ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Exact Sciences to Participate in June Investor Conferences
From Exact Sciences Corp.
Via Business Wire
News headline image
Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns ↗
We're heading into our third year of this raging bull market, and there doesn't appear to be any end in sight for these high-return stocks. 
Via InvestorPlace
News headline image
Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test ↗
The companies are likely to soon battle it out in the colon cancer screening market. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.